



PATENT

Attorney Docket No. P05375US1

1632
#101
NW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: The Pennsylvania State University Group Art Unit: 1632
SERIAL NO: 10/006,403 Examiner:
FILED: December 5, 2001 Confirmation No: 4264
TITLE: A MONOCLONAL ANTIBODY-BASED
DIAGNOSTIC ASSAY FOR GAMMA FIBRINOGEN

RECEIVED
NOV 01 2002
TECH CENTER 1600/290X

**INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING DATE OF EITHER A FINAL ACTION
OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This information disclosure statement is being filed *before* the mailing date of either a final action under § 1.113 or a notice of allowance under § 1.311, whichever occurs first.

Attached are Forms PTO/SB/08A and 08B (formerly Form PTO-1449) listing the relevant art known to the applicant herein. The Examiner is requested to consider the references and make them of record. This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior application Serial No. 60/251,291, filed on December 5, 2000. This application also relies, under 35 U.S.C. § 120, on the earlier filing date of prior PCT application Serial No. PCT/US01/47208, filed on December 5, 2001. The following references were submitted to, and/or cited by, the Patent Office in the prior application(s) and, therefore, are not required to be provided in this application: (*U.S. Documents*: Humes, et al.; Mosesson, et al.; Altieri et al.; Soe et al.; Edwards et al.; Ginsberg, Mark H.; Kraus et al.; Flow et al.; Frelinger, III et al.; Fickenscher, Karl; Ginsberg, Mark H.; Bundesen et al.; Kudryk et al.; Hawiger et al.; and Hawiger, et al.; *Foreign Patent Documents*: 2-84175 Japanese Patent 1990; PCT/US87/02125

CERTIFICATE OF MAILING

I hereby certify that the above correspondence was mailed to the Assistant Commissioner for Patents, Washington, D.C. 20231, as First Class mail, postage prepaid, this 24th day of October, 2002.

Wendy K. Marsh

March 10, 1998, American Biogenetic Sciences, Inc., Ploplis, et al.; and *Other – Non-Patent Documents*: Drouet et al.; "Plasma y'/y fibrinogen ratio, a marker of arterial thrombotic activity: a new potential cardiovascular risk factor?"; Blood Coagulation and Fibrinolysis 1999 Vol. 10 (suppl 1); pages S35 – S39; Lippincott Williams & Wilkins; Paris, France.)

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose. Legible copies of all items listed in Forms PTO/SB/08A and 08B (formerly Form PTO-1449) accompany this information statement.


Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

Authorization is hereby made to charge any additional fees required by this paper or credit any overpayment to Deposit Account 26-0084. A duplicate of this paper is attached.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. (Notice of January 9, 1992, 1135 O.G. 13-25, at 25.)

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Wendy K. Marsh", is written over the printed name and firm name.

Wendy K. Marsh, Reg. No. 39,705
McKEE, VOORHEES & SEASE, P.L.C.
801 Grand Avenue, Suite 3200
Des Moines, Iowa 50309-2721
Phone No. (515) 288-3667
Fax No. (515) 288-1338
CUSTOMER NO: 22885

-jc-

Attorneys of Record

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

Complete if Known

Application Number	10/006,403
Filing Date	December 5, 2001
First Named Inventor	Farrell, David H.
Group Art Unit	1632
Examiner Name	
Attorney Docket Number	P05375US1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

[illegible]

RECEIVED
NOV 01 2002
TECH CENTER 1600/2900

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.